Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Clinical Trial of SDTM001 Injection as Adjuvant Treatment for NSCLC Patients With Driver-gene-negative and Negative PD-L1 Expression After Radical Surgical Resection

NCT07096882 is registered in ClinicalTrials.gov with Cytocraft Biopharmaceutical Co., Ltd. as lead sponsor.

NCT NCT07096882
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07096882 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Clinical Trial of SDTM001 Injection as Adjuvant Treatment for NSCLC Patients With Driver-gene-negative and Negative PD-L1 Expression After Radical Surgical Resection
Lead sponsor
Cytocraft Biopharmaceutical Co., Ltd.
Phase
Phase 1
Overall status
Recruiting
Start date
July 26, 2025
Completion date
June 26, 2029
Enrollment
22 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer